Walter Hanel
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Articles (8)
Year:
2026
Year:
2026
Introduction High-dose systemic methotrexate (HD-MTX) in doses ≥ 3 g/m 2 is the cornerstone of treatment for central nervous system (CNS) lymphomas and prophylaxis for patients with high-risk of CNS relapse. Its administration requires extensive supportive care until serum clearance is achieved. Risk factors for delayed methotrexate (MTX) clearance and renal injury are well-characterized and include baseline renal function, age, and hypoalbuminemia. Data assessing characteristics associated with slow terminal clearance are lacking. Methods We performed a single-center, retrospective cohort study between 1/2015 to 10/2023 to evaluate characteristics associated with the rate of MTX clearance in the 72 h after serum MTX levels decline to below 0.2 µmol/L in adult patients with lymphoma who received MTX at doses ≥ 3 g/m 2 . MTX administration was evaluated at the cycle level with slow terminal clearance (STC) defined as > 72 h to clear from 30 kg/m 2 , first MTX level > 10.0 µmol/L, and acute kidney injury (AKI) after MTX administration were significantly associated with STC. Conclusion Utilizing clinically and statistically significant variables from our analyses, we advocate for the development and validation of a model to inform supportive care management once MTX levels decline below 0.2 µmol/L.
Year:
2026
Purpose: Mantle cell lymphoma (MCL) remains incurable despite therapeutic advances, highlighting the need for improved preclinical models. Existing transgenic MCL mouse models have significant limitations, restricting their translational value. Experimental Design: We generated an immunocompetent MCL model by overexpressing the key oncogenic drivers SRY-box transcription factor 11 (SOX11) and Cyclin D1 (CCND1) under the Eµ enhancer in C57BL/6 mice, aiming to replicate human MCL’s biological and pathologic features. Results: Eµ-SOX11CCND1 mice developed lymphoma marked by clonal B1a cell expansion in lymphatic and extranodal tissues. Morphologic, immunophenotypic, and transcriptional profiling revealed strong similarity to human MCL, with pathway analysis confirming significant molecular overlap. Importantly, lymphoma cells could be adoptively transferred into wild-type recipients, enabling therapeutic testing within an intact immune system. Conclusions: The Eµ-SOX11CCND1 mouse represents a robust and biologically relevant model that faithfully recapitulates human MCL. Its immunocompetent nature and adoptive transfer capability make it a valuable model for studying disease mechanisms and evaluating novel therapeutic approaches for patients with MCL.
Year:
2025
Purpose: Mantle cell lymphoma (MCL) remains incurable despite therapeutic advances, highlighting the need for improved preclinical models. Existing transgenic MCL mouse models have significant limitations, restricting their translational value. Experimental Design: We generated an immunocompetent MCL model by overexpressing the key oncogenic drivers SRY-box transcription factor 11 ( SOX11 ) and Cyclin D1 ( CCND1) under the Eµ enhancer in C57BL/6 mice, aiming to replicate human MCL’s biological and pathologic features. Results: Eµ-SOX11CCND1 mice developed lymphoma marked by clonal B1a cell expansion in lymphatic and extranodal tissues. Morphologic, immunophenotypic, and transcriptional profiling revealed strong similarity to human MCL, with pathway analysis confirming significant molecular overlap. Importantly, lymphoma cells could be adoptively transferred into wild-type recipients, enabling therapeutic testing within an intact immune system. Conclusions: The Eµ-SOX11CCND1 mouse represents a robust and biologically relevant model that faithfully recapitulates human MCL. Its immunocompetent nature and adoptive transfer capability make it a valuable model for studying disease mechanisms and evaluating novel therapeutic approaches for patients with MCL.
Year:
2025
Year:
2024
Year:
2023
Year:
2023
Collaborators (22)
Laura Hilton
Staff Scientist
Simon Fraser University
Alice Mims
Ohio State University
Cem Meydan
Assistant Professor
Weill Cornell Medicine
Robert Baiocchi
-
Parvathi Ranganathan
Associate Professor with Tenure
Ohio State University
Rosa Lapalombella
Ohio State University
John Reneau
Ohio State University
Lapo Alinari
Ohio State University
XIAOLI ZHANG
Professor
University of South Florida
chunhua song
Associate Professor
Ohio State University
Narendranath Epperla
The Ohio State University Comprehensive Cancer Center
Satishkumar Singh
Ohio State University
Yazeed Sawalha
The Ohio State University Comprehensive Cancer Center
Samir Parekh
Director, Center of Excellence for Multiple Myeloma
Icahn School of Medicine at Mount Sinai
Wing Keung Chan
Assistant Professor
Ohio State University
Robert Faryabi
Associate Professor
University of Pennsylvania
David Bond
Associate Professor
Ohio State University
Blake Peterson
Professor and Chair
Ohio State University
Lalit Sehgal
Associate Professor
Ohio State University
Violetta Leshchenko
Senior Scientist
Icahn School of Medicine at Mount Sinai
Timothy Voorhees
Associate Professor of Clinical Internal Medicine
The Ohio State University Wexner Medical Center
Christopher Mason
Professor
Weill Cornell Medical College
Make your next move.
Prepare your application
Review drafts before you send them.